Literature DB >> 11771669

Chondrogenic activity of the heparan sulfate proteoglycan perlecan maps to the N-terminal domain I.

Margaret M French1, Ronald R Gomes, Rupert Timpl, Magnus Höök, Kirk Czymmek, Mary C Farach-Carson, Daniel D Carson.   

Abstract

C3H10T1/2 cells differentiate along a chondrogenic pathway when plated onto the extracellular matrix (ECM) protein perlecan (Pln). To identify the region(s) within the large Pln molecule that provides a differentiation signal, recombinant Pln-sequence-based polypeptides representing distinct structural domains were assayed for their ability to promote chondrogenesis in C3H10T1/2 cells. Five distinct domains, along with structural variations, were tested. The N-terminal domain I was tested in two forms (IA and IB) that contain only heparan sulfate (HS) chains or both HS and chondroitin sulfate (CS) chains, respectively. A mutant form of domain I lacking attachment sites for both HS and CS (Pln I(mut)) was tested also. Other constructs consecutively designated Pln domains II, III(A-C), IV(A,B), and V(A,B) were used to complete the structure-function analysis. Cells plated onto Pln IA or Pln IB but no other domain rapidly assembled into cellular aggregates of 40-120 microm on average. Aggregate formation was dependent on the presence of glycosaminoglycan (GAG) chains, because Pln I-based polypeptides lacking GAG chains either by enzymatic removal or mutation of HS/CS attachment sites were inactive. Aggregates formed on GAG-bearing Pln IA stained with Alcian Blue and were recognized by antibodies to collagen type II and aggrecan but were not recognized by an antibody to collagen type X, a marker of chondrocyte hypertrophy. Collectively, these studies indicate that the GAG-bearing domain I of Pln provides a sufficient signal to trigger C3H10T1/2 cells to enter a chondrogenic differentiation pathway. Thus, this matrix proteoglycan (PG) found at sites of cartilage formation in vivo is likely to enhance early stage differentiation induced by soluble chondrogenic factors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11771669      PMCID: PMC1774590          DOI: 10.1359/jbmr.2002.17.1.48

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  28 in total

1.  Recombinant domain IV of perlecan binds to nidogens, laminin-nidogen complex, fibronectin, fibulin-2 and heparin.

Authors:  M Hopf; W Göhring; E Kohfeldt; Y Yamada; R Timpl
Journal:  Eur J Biochem       Date:  1999-02

2.  Perlecan is essential for cartilage and cephalic development.

Authors:  E Arikawa-Hirasawa; H Watanabe; H Takami; J R Hassell; Y Yamada
Journal:  Nat Genet       Date:  1999-11       Impact factor: 38.330

3.  Ablation of the PTHrP gene or the PTH/PTHrP receptor gene leads to distinct abnormalities in bone development.

Authors:  B Lanske; M Amling; L Neff; J Guiducci; R Baron; H M Kronenberg
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

4.  Temporal and spatial expressions of transforming growth factor-betas and their receptors in epiphyseal growth plate.

Authors:  S Matsunaga; T Yamamoto; K Fukumura
Journal:  Int J Oncol       Date:  1999-06       Impact factor: 5.650

5.  The C-terminal domain V of perlecan promotes beta1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans.

Authors:  J C Brown; T Sasaki; W Göhring; Y Yamada; R Timpl
Journal:  Eur J Biochem       Date:  1997-11-15

6.  High density micromass cultures of embryonic limb bud mesenchymal cells: an in vitro model of endochondral skeletal development.

Authors:  M A Mello; R S Tuan
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-05       Impact factor: 2.416

7.  Human perlecan immunopurified from different endothelial cell sources has different adhesive properties for vascular cells.

Authors:  J M Whitelock; L D Graham; J Melrose; A D Murdoch; R V Iozzo; P A Underwood
Journal:  Matrix Biol       Date:  1999-04       Impact factor: 11.583

8.  Inhibition of glycosaminoglycan modification of perlecan domain I by site-directed mutagenesis changes protease sensitivity and laminin-1 binding activity.

Authors:  T Sasaki; M Costell; K Mann; R Timpl
Journal:  FEBS Lett       Date:  1998-09-18       Impact factor: 4.124

9.  Expression of the heparan sulfate proteoglycan, perlecan, during mouse embryogenesis and perlecan chondrogenic activity in vitro.

Authors:  M M French; S E Smith; K Akanbi; T Sanford; J Hecht; M C Farach-Carson; D D Carson
Journal:  J Cell Biol       Date:  1999-05-31       Impact factor: 10.539

10.  Perlecan maintains the integrity of cartilage and some basement membranes.

Authors:  M Costell; E Gustafsson; A Aszódi; M Mörgelin; W Bloch; E Hunziker; K Addicks; R Timpl; R Fässler
Journal:  J Cell Biol       Date:  1999-11-29       Impact factor: 10.539

View more
  28 in total

1.  Perlecan-stimulated nodules undergo chondrogenic maturation in response to rhBMP-2 treatment in vitro.

Authors:  Ronald R Gomes; Mary C Farach Carson; Daniel D Carson
Journal:  Connect Tissue Res       Date:  2003       Impact factor: 3.417

2.  Potential of exogenous cartilage proteoglycan as a new material for cartilage regeneration.

Authors:  Shusa Ohshika; Yasuyuki Ishibashi; Atsushi Kon; Tomomi Kusumi; Hiroshi Kijima; Satoshi Toh
Journal:  Int Orthop       Date:  2011-08-12       Impact factor: 3.075

Review 3.  Progranulin: a growth factor, a novel TNFR ligand and a drug target.

Authors:  Chuan-ju Liu; Xavier Bosch
Journal:  Pharmacol Ther       Date:  2011-10-08       Impact factor: 12.310

4.  A novel peptide sequence in perlecan domain IV supports cell adhesion, spreading and FAK activation.

Authors:  Mary C Farach-Carson; Anissa J Brown; Megan Lynam; Jeffrey B Safran; Daniel D Carson
Journal:  Matrix Biol       Date:  2007-10-10       Impact factor: 11.583

5.  Perlecan: an important component of the cartilage pericellular matrix.

Authors:  R Gomes; C Kirn-Safran; M C Farach-Carson; D D Carson
Journal:  J Musculoskelet Neuronal Interact       Date:  2002-12       Impact factor: 2.041

6.  Perlecan domain I-conjugated, hyaluronic acid-based hydrogel particles for enhanced chondrogenic differentiation via BMP-2 release.

Authors:  Amit K Jha; Weidong Yang; Catherine B Kirn-Safran; Mary C Farach-Carson; Xinqiao Jia
Journal:  Biomaterials       Date:  2009-09-23       Impact factor: 12.479

Review 7.  Perlecan and tumor angiogenesis.

Authors:  Xinnong Jiang; John R Couchman
Journal:  J Histochem Cytochem       Date:  2003-11       Impact factor: 2.479

8.  Heparanase expression and activity influences chondrogenic and osteogenic processes during endochondral bone formation.

Authors:  A J Brown; M Alicknavitch; S S D'Souza; T Daikoku; C B Kirn-Safran; D Marchetti; D D Carson; M C Farach-Carson
Journal:  Bone       Date:  2008-06-06       Impact factor: 4.398

9.  Perlecan domain IV peptide stimulates salivary gland cell assembly in vitro.

Authors:  Swati Pradhan; Chu Zhang; Xinqiao Jia; Daniel D Carson; Robert Witt; Mary C Farach-Carson
Journal:  Tissue Eng Part A       Date:  2009-11       Impact factor: 3.845

Review 10.  Heparan sulfate proteoglycans: a GAGgle of skeletal-hematopoietic regulators.

Authors:  Kathryn D Rodgers; James D San Antonio; Olena Jacenko
Journal:  Dev Dyn       Date:  2008-10       Impact factor: 3.780

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.